There has been great engagement in accountable care organizations (ACOs) because ACOs offer a level of coordinated care that patients are looking for, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
There has been great engagement in accountable care organizations (ACOs) because ACOs offer a level of coordinated care that patients are looking for, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
Transcript
What success has UnitedHealthcare seen with its Nexus ACO that it expects it to continue growing?
The biggest success factor that we’ve seen with our Nexus product is the engagement and satisfaction of the members that have selected that product. They really feel that their providers care about them. They’re seeing a more coordinated level of care, and I think that’s the biggest selling point for this product—besides the price point for the employer—it’s the results that the members are seeing.
Why is interest in ACOs growing among commercial payers?
From my perspective, the reason interest is growing in ACOs is cause patients are looking for somebody to help coordinate their care. I know as a personal example, my wife several years ago was diagnosed with breast cancer, and she had to coordinate care, or we had to coordinate the care, between the general surgeon who removed the lump between the plastic surgeon between her oncologist. It was us serving as that go-between for all these different providers making sure that tests were done making sure that results got from one physician to another.
Whereas with an ACO, if that ACO is truly performing at its optimal capabilities, they’re going to coordinate that care for the member, they’re going to make them member feel supported, which I think employers are looking for when employers are trying to decide: where do we want our members to get their care? Where do we want our members to experience care? They’re coming to payers like UnitedHealthcare that offer just such an experience.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More